Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib Plus Cetuximab in Neoadjuvant BRAF V600E Colorectal Cancer
NCT05706779Phase 2Recruiting
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib in colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Started Feb 2023; status: recruiting.
02
Drugs
encorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05706779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05706779.